Cover Image
Market Research Report

Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast in 23 Major Markets 2018-2028

Published by Black Swan Analysis Product code 355843
Published Content info 66 Pages
Delivery time: 1-2 business days
Price
Back to Top
Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast in 23 Major Markets 2018-2028
Published: September 1, 2018 Content info: 66 Pages
Description

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Primary Immunodeficiency Diseases in 23 Major Markets

Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system. The result is a compensatory, often exaggerated and chronic inflammatory response by less effective alternative immune pathways, which damage not only infected cells but also surrounding tissue.

This report provides the current prevalent population for PID across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Sweden, Austria, Switzerland, Greece, Czech Republic, Hungary, Turkey, Japan, China, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, PID patients grouped by disease classification have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PID include:

  • Severe Congenital Immunodeficiency (SCID)
  • Recurrent or persistent infections
  • Allergic manifestations
  • Respiratory diseases
  • Organ problems
  • Developmental delay

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global PID market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of PID and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Identification of PID patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of PID patients.

Table of Contents
Product Code: PRID0020918

Table of Contents

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR PRIMARY IMMUNODEFICIENCY DISEASES
  • FEATURES OF PRIMARY IMMUNODEFICIENCY DISEASES PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of PID, total (000s)
  • Table 2. Prevalence of PID, males (000s)
  • Table 3. Prevalence of PID, females (000s)
  • Table 4. PID patients by classification, total (000s)
  • Table 5. Abbreviations and acronyms used in the report
  • Table 6. USA prevalence of PID by 5-yr age cohort, males (000s)
  • Table 7. USA prevalence of PID by 5-yr age cohort, females (000s)
  • Table 8. Canada prevalence of PID by 5-yr age cohort, males (000s)
  • Table 9. Canada prevalence of PID by 5-yr age cohort, females (000s)
  • Table 10. France prevalence of PID by 5-yr age cohort, males (000s)
  • Table 11. France prevalence of PID by 5-yr age cohort, females (000s)
  • Table 12. Germany prevalence of PID by 5-yr age cohort, males (000s)
  • Table 13. Germany prevalence of PID by 5-yr age cohort, females (000s)
  • Table 14. Italy prevalence of PID by 5-yr age cohort, males (000s)
  • Table 15. Italy prevalence of PID by 5-yr age cohort, females (000s)
  • Table 16. Spain prevalence of PID by 5-yr age cohort, males (000s)
  • Table 17. Spain prevalence of PID by 5-yr age cohort, females (000s)
  • Table 18. UK prevalence of PID by 5-yr age cohort, males (000s)
  • Table 19. UK prevalence of PID by 5-yr age cohort, females (000s)
  • Table 20. Poland prevalence of PID by 5-yr age cohort, males (000s)
  • Table 21. Poland prevalence of PID by 5-yr age cohort, females (000s)
  • Table 22. Netherlands prevalence of PID by 5-yr age cohort, males (000s)
  • Table 23. Netherlands prevalence of PID by 5-yr age cohort, females (000s)
  • Table 24. Belgium prevalence of PID by 5-yr age cohort, males (000s)
  • Table 25. Belgium prevalence of PID by 5-yr age cohort, females (000s)
  • Table 26. Sweden prevalence of PID by 5-yr age cohort, males (000s)
  • Table 27. Sweden prevalence of PID by 5-yr age cohort, females (000s)
  • Table 28. Austria prevalence of PID by 5-yr age cohort, males (000s)
  • Table 29. Austria prevalence of PID by 5-yr age cohort, females (000s)
  • Table 30. Switzerland prevalence of PID by 5-yr age cohort, males (000s)
  • Table 31. Switzerland prevalence of PID by 5-yr age cohort, females (000s)
  • Table 32. Greece prevalence of PID by 5-yr age cohort, males (000s)
  • Table 33. Greece prevalence of PID by 5-yr age cohort, females (000s)
  • Table 34. Czech Republic prevalence of PID by 5-yr age cohort, males (000s)
  • Table 35. Czech Republic prevalence of PID by 5-yr age cohort, females (000s)
  • Table 36. Hungary prevalence of PID by 5-yr age cohort, males (000s)
  • Table 37. Hungary prevalence of PID by 5-yr age cohort, females (000s)
  • Table 38. Turkey prevalence of PID by 5-yr age cohort, males (000s)
  • Table 39. Turkey prevalence of PID by 5-yr age cohort, females (000s)
  • Table 40. Japan prevalence of PID by 5-yr age cohort, males (000s)
  • Table 41. Japan prevalence of PID by 5-yr age cohort, females (000s)
  • Table 42. China prevalence of PID by 5-yr age cohort, males (000s)
  • Table 43. China prevalence of PID by 5-yr age cohort, females (000s)
  • Table 44. India prevalence of PID by 5-yr age cohort, males (000s)
  • Table 45. India prevalence of PID by 5-yr age cohort, females (000s)
  • Table 46. Brazil prevalence of PID by 5-yr age cohort, males (000s)
  • Table 47. Brazil prevalence of PID by 5-yr age cohort, females (000s)
  • Table 48. Mexico prevalence of PID by 5-yr age cohort, males (000s)
  • Table 49. Mexico prevalence of PID by 5-yr age cohort, females (000s)
  • Table 50. Argentina prevalence of PID by 5-yr age cohort, males (000s)
  • Table 51. Argentina prevalence of PID by 5-yr age cohort, females (000s)
Back to Top